In 2024, Geistlich reached even more patients worldwide. Despite difficult global market conditions, particularly in China, and the strong Swiss franc, Geistlich was able to expand its position. Market development was particularly encouraging in the USA, Brazil, Japan and India, where Geistlich has its own affiliates. 
Geistlich was one of the first companies in the industry to receive the demanding certification according to the European Medical Device Regulation 2017/745 (MDR). ‘This confirms the high quality of our biomaterials and is a mark of trust for us,’ says Diego Gabathuler, CEO of Geistlich. 
Geistlich has achieved a milestone in the treatment of skin cancer and head injuries. The collagen matrix Geistlich Mucograft® has been approved in Europe as a gentle alternative to skin grafts. 

Targeted investments for the benefit of patients 
Strategic acquisitions and partnerships play a central role in Geistlich’s growth strategy. The acquisition of the Brazilian medical technology company Bionnovation Biomedical is an important step towards expansion in emerging markets. In the US, Geistlich entered an exclusive distribution partnership with Stimlabs for Derma-Gide®, a complex wound matrix for wounds that are difficult to heal. In addition, Geistlich acquired a stake in the French company O.S.T. Développement, which specializes in biomaterials derived from human donor tissue. 

Geistlich continues to grow 
With its latest investment in the German company ReOss, Geistlich is investing in digital innovation. By expanding computer-aided processes, the company aims to create more precise, customized solutions, reduce treatment times, and improve patient care. Despite volatile global markets and challenging currency conditions, the family-owned company continues to invest in its portfolio. Geistlich is expanding its product range specifically for growing markets, Dental Service Organizations (DSO) and general practitioners. “Our goal is to make our regenerative products available to an even larger group through partnerships and our own developments,” says Diego Gabathuler, “Medical regeneration is crucial for good health and a high quality of life.”